ライフサイエンスコーパス: mesothelin

1 , epithelial cellular adhesion molecule, and mesothelin.

2 so produces regressions of tumors expressing mesothelin.

3 h an eukaryotic expression vector coding for mesothelin.

4 C and is very cytotoxic to cells expressing mesothelin.

5 ize highly immunogenic Region I (296-390) on mesothelin.

6 the immunotoxin SS1P that binds Region I of mesothelin.

7 -cell immunity to cancer antigens, including mesothelin.

8 oadhesin HN125 to interfere MUC16 binding to mesothelin.

9 oses of SS1P, a RIT whose Ab portion targets mesothelin.

10 rine mesothelioma line that stably expresses mesothelin.

11 ined in the first 64-residue fragment of the mesothelin.

12 imeric receptor with high affinity for human mesothelin.

13 mor cells are focally positive for CA125 and mesothelin.

14 ted proteinase and inhibitor of metastasis), mesothelin (a cancer marker), marapsin (a trypsin-like s

15 trikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in

16 After three rounds of panning on recombinant mesothelin, a single-chain Fv (scFv)-displaying phage wa

17 lignant mesothelioma frequently express both mesothelin and CA125 (also known as MUC16) at high level

18 The interaction between mesothelin and CA125 may facilitate the implantation and

19 of ovarian cancer cells by interacting with mesothelin and galectin.

20 otoxicity of immunotoxin SS1P, which targets mesothelin and is currently in clinical trials for the t

21 id sequence as the membrane-bound portion of mesothelin and megakaryocyte potentiating factor (MPF).

22 ected that bound specifically to recombinant mesothelin and mesothelin-positive cells.

23 a single-chain variable fragment that binds mesothelin and that is fused to signaling domains derive

24 an carcinomas were PAX8 (paired box gene 8), mesothelin, and ephrin-B1 (EFNB1).

25 alin2, 14-3-3sigma, trefoil factor2, S100A4, mesothelin, and prostate stem cell antigen) that were ov

26 as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation.

27 mino acids at the N-terminal of cell surface mesothelin as the minimum fragment for complete binding

28 ving mesothelioma, a positive blood test for mesothelin at a high-specificity threshold is a strong i

29 f mesothelin shedding and could help improve mesothelin-based targeted therapies.

30 The protein has been named mesothelin because it is made by mesothelial cells.

31 These antibodies do not compete for mesothelin binding with the immunotoxin SS1P that binds

32 r of mesenchymal markers including vimentin, mesothelin, bone morphogenetic protein 7, and Tweak rece

33 zes this CA125-binding domain and blocks the mesothelin-CA125 interaction on cancer cells.

34 ogous human T cells electroporated with anti-mesothelin CAR mRNA.

35 n addition, a mesothelin tumor vaccine and a mesothelin- chimeric antigen receptor are being evaluate

36 However, the poor sensitivity of mesothelin clearly limits its added value to early diagn

37 new assay can also be used to measure serum mesothelin concentration in mesothelioma patients, indic

38 attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen

39 009, a humanized monoclonal antibody against mesothelin currently under clinical trials.

40 imeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab r

41 ucted via monitoring the cytotoxicity of the mesothelin-directed immunotoxin SS1P.

42 n anti-mesothelin immunotoxin, was the first mesothelin-directed therapy to enter the clinic, and its

43 At 95% specificity, mesothelin displayed a sensitivity of 32% (95% CI, 26% t

44 s to multiple HLA-A2, A3, and A24-restricted mesothelin epitopes exclusively in the three patients wi

45 ll lung cancer (NSCLC) line, one targeted to mesothelin expressed by a mesothelioma cell line, and on

46 RG7787 kills many types of mesothelin-expressing cancer cells lines and causes tumo

47 18 Fv that retains full binding affinity for mesothelin-expressing cancer cells.

48 therapeutic strategy to improve targeting of mesothelin-expressing cancers.

49 nitoring and treating mesothelioma and other mesothelin-expressing cancers.

50 SS1scFvSA localized in the mesothelin-expressing tumor, resulting in a high accumul

51 SS1P targets and kills mesothelin-expressing tumors, which include mesothlioma

52 optimized RIT consisting of a humanized anti-mesothelin Fab fused to domain III of Pseudomonas exotox

53 ent techniques to identify a binding site on mesothelin for CA125.

54 The mesothelin fragment has a compact, right-handed superhel

55 Our results demonstrate that mesothelin function is not essential for growth or repro

56 al genes in the immunotoxin pathway, such as mesothelin, furin, KDEL receptor 2, or members of the di

57 We prioritized mucin-1, mesothelin, gamma-glutamyltransferase 5, and cathepsin-E

58 We have analyzed the expression of the mouse mesothelin gene in different developmental stages and in

59 In adult tissues the mesothelin gene was expressed in lung, heart, spleen, li

60 vivo, we generated mutant mice in which the mesothelin gene was inactivated by replacing it with the

61 e ongoing studies will define the utility of mesothelin immunotherapy for treating cancer.

62 SS1P, an anti-mesothelin immunotoxin, was the first mesothelin-directe

63 218 and YP223) is suitable to detect soluble mesothelin in a sandwich ELISA with high sensitivity.

64 The use of mesothelin in early diagnosis was evaluated by different

65 ine the diagnostic accuracy and use of serum mesothelin in early diagnosis, we performed an individua

66 ol/L, the sensitivities and specificities of mesothelin in the different studies ranged widely from 1

67 To directly assess the function of the mesothelin in vivo, we generated mutant mice in which th

68 ultiple secondary structural elements of the mesothelin, including residues from helix alpha1, the lo

69 attenuated Listeria monocytogenes-expressing mesothelin, induces innate and adaptive immunity.

70 Mesothelin is a cell-surface glycoprotein whose expressi

71 Mesothelin is a cell-surface molecule over-expressed on

72 Mesothelin is a cell-surface tumor-associated antigen ex

73 Mesothelin is a differentiation antigen present on the s

74 Mesothelin is a glycoprotein that is overexpressed in se

75 Mesothelin is a glycosylphosphatidylinositol-linked glyc

76 Mesothelin is a tumor antigen that is highly expressed i

77 Mesothelin is a tumor differentiation antigen that is hi

78 Mesothelin is actively shed from the cell surface and is

79 Mesothelin is an antigen demonstrated previously by gene

80 Mesothelin is an emerging cell surface target in mesothe

81 Mesothelin is currently considered the best available se

82 Because among normal tissues, mesothelin is present only on mesothelial cells, it repr

83 When stimulated by mesothelin, lentivirally transduced T cells were induced

84 Mesothelin levels were standardized for between-study di

85 Mesothelin may play a role in cellular adhesion.

86 ch identified 16 diagnostic studies of serum mesothelin, measured with the Mesomark enzyme-linked imm

87 The conversion of the anti-mesothelin monoclonal antibody K1 to a single-chain Fv (

88 ins comprising either the N-terminal part of mesothelin/MPF (D1Ig), reported to be easily cleaved off

89 Soluble molecules of the mesothelin/MPF family may provide useful new marker(s) f

90 A new member of the mesothelin/MPF family was discovered, which has an 82-bp

91 In homozygous mutant mice neither mesothelin mRNA nor the protein product was detected.

92 Mesothelin (MSLN) and cancer antigen125/mucin 16 (CA125/

93 Mesothelin (MSLN) may be the most "dramatic" of the tumo

94 We apply this paradigm to study mesothelin (MSLN) overexpression, a nearly ubiquitous, d

95 ibulin 2, and the recently identified marker mesothelin (MSLN).

96 ially expressed genes identified by PCA were Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutamina

97 crystal structure of the complex between the mesothelin N-terminal fragment and Fab of MORAb-009 at 2

98 Binding of mesothelin on normal mesothelial cells lining the pleura

99 The limited expression of mesothelin on normal tissues and its high expression in

100 and RG7787 act synergistically to kill many mesothelin-positive cancer cell lines and produce major

101 d specifically to recombinant mesothelin and mesothelin-positive cells.

102 via a bystander mechanism and protected the mesothelin-positive targets from apoptosis rather than l

103 ently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in p

104 RG7787 (anti-mesothelin recombinant immunotoxin) is highly cytotoxic

105 We have found that mesothelin sheddase activity is mediated by a TNF-alpha

106 dings provide a mechanistic understanding of mesothelin shedding and could help improve mesothelin-ba

107 act through TACE as endogenous regulators of mesothelin shedding.

108 th CARs specific for the human tumor antigen mesothelin showed greatly enhanced cytokine production a

109 vidual tumor cells along with levels of shed mesothelin (sMSLN), a barrier of SS1P therapy.

110 survival and toxicity, and the induction of mesothelin specific T cell responses.

111 immunotoxin composed of the Fv portion of a mesothelin-specific antibody fused to a bacterial toxin

112 Enhanced mesothelin-specific CD8 T-cell responses were associated

113 ddition, the post-immunotherapy induction of mesothelin-specific CD8+ T cells in HLA-A1+ and HLA-A2+p

114 ntigen-related cell adhesion molecule 6, and mesothelin, suggest potential use as diagnostic markers.

115 Incorporation of a spacer-into the mesothelin surface antigen or the cancer drug itself-con

116 ed (PD-1-mediated) T cell exhaustion affects mesothelin-targeted CAR T cells and explored cell-intrin

117 RG7787 is a mesothelin-targeted immunotoxin designed to have low-imm

118 to enter the clinic, and its use showed that mesothelin-targeted therapy was safe in patients.

119 While in the process of characterizing mesothelin-targeted TR3 variants using a single chain an

120 s required and sufficient for the binding of mesothelin to CA125.

121 The 2.5-kb mesothelin transcript was detected in the mRNA of E 7.0,

122 The A431-K5 mesothelin transfected cell line was used as the target.

123 In addition, a mesothelin tumor vaccine and a mesothelin- chimeric anti

124 mor responses have prompted us to review how mesothelin was discovered and the advances that led to t

125 or developments over the past 20 years since mesothelin was first identified in our laboratory.

126 rmalities were detected in any tissues where mesothelin was reportedly expressed in wild-type mice.

127 revealed that claudin 4, CXCR4, S100A4, and mesothelin were expressed at significantly high frequenc

128 expression of cell surface antigens such as mesothelin, which is overexpressed in mesothelioma, ovar

129 The purified immunotoxin binds mesothelin with high affinity (Kd 11 nm), is stable for